来源:[1] Rybelsus更新的欧盟标签能否推动诺和诺德的新的增长潜力? (https://finance.yahoo.com/news/rybelsus-updat ...)[2] 欧盟批准Rybelsus心脏益处标签后,诺和诺德股价上涨 - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)[3] 诺和诺德(CPSE:NOVO B)在Rybelsus赢得欧盟心血管标签更新后上涨5.2%——牛市案例改变了吗? - Simply Wall St (https://vertexaisearch.cloud.google.com/groun ...)